Latest Moberg Pharma News & Updates
See the latest news and media coverage for Moberg Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish dermatology pharmaceutical company
mobergpharma.se- Headquarters
- Bromma, Sweden
- Founded year
- 2006
- Company type
- Public company
- Number of employees
- 15–50
Last updated
Latest news about Moberg Pharma
In short: Moberg Pharma expanded its partnership with Karo Healthcare for Terclara® and achieved market leadership in Sweden and Norway.
Company announcements
-
Moberg Pharma expands collaboration with Karo Healthcare
The agreement extends MOB-015/Terclara marketing to Australia, New Zealand, South Korea, and Taiwan. It includes royalties and regulatory approvals.
-
Moberg Pharma convenes Annual General Meeting
The meeting occurs on 21 May 2026 in Stockholm, with proposals for board elections, remuneration principles, LTI 2026, and articles amendment.
-
Moberg Pharma releases annual report 2025
The report is published in accordance with EU Market Abuse Regulation on April 17, 2026. Contact details for CEO Anna Ljung and CFO Mark Beveridge are provided.
-
Moberg Pharma publishes year-end report 2025
Net revenue SEK 13.5M, EBITDA -SEK 25.7M. Enters exclusive license with Karo Healthcare for Terclara® in 19 European markets.
Media coverage
-
Moberg Pharma reduces loss
Moberg Pharma's operating result amounted to -7.5 million kronor for the fourth quarter of 2025 (-308). Sales amounted to 2.1 million kronor (1.0). The net result was -12.8 million...
-
Moberg Pharma Expands European Market Reach with New License Agreement
Moberg Pharma AB ( (SE:MOB)) has provided an update. Moberg Pharma AB has announced a significant expansion into the European market through an exclusive license...
-
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of...
-
Moberg Pharma AB
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the...
Track Moberg Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore